Appendix 4G and Corporate Governance Statement
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read MoreDividend/Distribution – CUV
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read MoreAppendix 4E & Annual Report
Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...
Read MoreNotification regarding unquoted securities
CLINUVEL today released a notification regarding unquoted securities.
Read MoreTwo grounds of Appeal upheld by NICE Panel
In an announcement released today, CLINUVEL provided an updated on the outcome...
Read MoreNotification of cessation of securities
CLINUVEL today released a notification regarding cessation of securities.
Read MoreChange of Director’s Interest Notice
CLINUVEL today released a notification regarding a change of Director’s interest.
Read MoreCLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients
CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...
Read MoreExpansion of CLINUVEL’s global porphyria programs
CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...
Read MoreInvestor Presentation - NYC Nasdaq Event
CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...
Read MoreFirst stroke patient treated with PRÉNUMBRA® Instant
CLINUVEL has started its second stroke trial (CUV803) with the first patient...
Read MoreStatement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCommercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read MoreRelief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More